BRISTOL-MYERS SQUIBB COMPANY Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation of $8.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2024 was $8.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2022 was $9.00M, a 80.00% increase from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2021 was $5.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, decrease resulting from foreign currency translation for fiscal 2019 was $1.00M, a 83.33% decline from fiscal 2018.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation 12 month |
|---|---|
| 2024-12-31 | $8.00M 10-K · filed 2026-02-11 |
| 2022-12-31 | $9.00M 10-K · filed 2025-02-12 |
| 2021-12-31 | $5.00M 10-K · filed 2024-02-13 |
| 2019-12-31 | $1.00M 10-K · filed 2022-02-09 |
| 2018-12-31 | $6.00M 10-K · filed 2021-02-10 |
| 2016-12-31 | $9.00M 10-K · filed 2019-02-25 |
| 2015-12-31 | $10.00M 10-K · filed 2018-02-13 |
| 2014-12-31 | $12.00M 10-K · filed 2017-02-21 |
| 2011-12-31 | $5.00M 10-K · filed 2014-02-14 |
| 2010-12-31 | $1.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |